Lee J, Kanwar B, Khattak A, Altschuler E, Sergi C, Lee S
Naunyn Schmiedebergs Arch Pharmacol. 2023; 396(7):1501-1511.
PMID: 36773052
PMC: 9918834.
DOI: 10.1007/s00210-023-02407-7.
Hein D, Millner L
Expert Opin Drug Metab Toxicol. 2020; 17(1):9-21.
PMID: 33094670
PMC: 7790970.
DOI: 10.1080/17425255.2021.1840551.
Ritschel W
Pharm Res. 2013; 3(3):173-7.
PMID: 24271525
DOI: 10.1023/A:1016370209604.
Karlsson E, Molin L, Norlander B, Sjoqvist F
Br J Clin Pharmacol. 2012; 1(6):467-75.
PMID: 22454932
PMC: 1402529.
DOI: 10.1111/j.1365-2125.1974.tb01696.x.
Miller A, Bandyopadhyay N, Wootton D, Duparc S, Kirby P, Winstanley P
Eur J Clin Pharmacol. 2009; 65(10):977-87.
PMID: 19517101
DOI: 10.1007/s00228-009-0672-1.
Bioactivation, protein haptenation, and toxicity of sulfamethoxazole and dapsone in normal human dermal fibroblasts.
Bhaiya P, Roychowdhury S, Vyas P, Doll M, Hein D, Svensson C
Toxicol Appl Pharmacol. 2006; 215(2):158-67.
PMID: 16603214
PMC: 1615915.
DOI: 10.1016/j.taap.2006.02.006.
Population pharmacokinetics of dapsone administered biweekly to human immunodeficiency virus-infected patients.
Gatti G, Merighi M, Hossein J, Travaini S, Casazza R, Karlsson M
Antimicrob Agents Chemother. 1996; 40(12):2743-8.
PMID: 9124833
PMC: 163614.
DOI: 10.1128/AAC.40.12.2743.
Zidovudine, trimethoprim, and dapsone pharmacokinetic interactions in patients with human immunodeficiency virus infection.
Lee B, Safrin S, Makrides V, Gambertoglio J
Antimicrob Agents Chemother. 1996; 40(5):1231-6.
PMID: 8723472
PMC: 163297.
DOI: 10.1128/AAC.40.5.1231.
Pharmacokinetics and protein binding interactions of dapsone and pyrimethamine.
Ahmad R, Rogers H
Br J Clin Pharmacol. 1980; 10(5):519-24.
PMID: 7437265
PMC: 1430153.
DOI: 10.1111/j.1365-2125.1980.tb01798.x.
Determination of the acetylator phenotype and pharmacokinetics of some sulphonamides in man.
Vree T, OREILLY W, Hekster Y, Damsma J, van der Kleijn E
Clin Pharmacokinet. 1980; 5(3):274-94.
PMID: 7389236
DOI: 10.2165/00003088-198005030-00006.
Plasma and salivary pharmacokinetics of dapsone estimated by a thin layer chromatographic method.
Ahmad R, Rogers H
Eur J Clin Pharmacol. 1980; 17(2):129-33.
PMID: 7371704
DOI: 10.1007/BF00562621.
A liner mode of reversible metabolism and its application to bioavailability assessment.
Hwang S, Kwan K, Albert K
J Pharmacokinet Biopharm. 1981; 9(6):693-709.
PMID: 7341755
DOI: 10.1007/BF01070901.
Acetylator phenotyping: a comparison of the isoniazid and dapsone tests.
Hanson A, Melander A
Eur J Clin Pharmacol. 1981; 20(3):233-4.
PMID: 7286042
DOI: 10.1007/BF00544604.
Effects of concurrent administration of other substrates of N-acetyltransferase on dapsone acetylation.
Ahmad R, Rogers H, Vandenburg M, Wright P
Br J Clin Pharmacol. 1981; 12(1):83-6.
PMID: 7248142
PMC: 1401758.
DOI: 10.1111/j.1365-2125.1981.tb01860.x.
The hypotensive response to hydralazine, in triple therapy, is not related to acetylator phenotype.
Vandenburg M, Wright P, Holmes J, Rogers H, Ahmad R
Br J Clin Pharmacol. 1982; 13(5):747-50.
PMID: 7082547
PMC: 1402085.
DOI: 10.1111/j.1365-2125.1982.tb01452.x.
Isoniazid disposition, comparison of isoniazid phenotyping methods in and acetylator distribution of Japanese patients with idiopathic systemic lupus erythematosus and control subjects.
Horai Y, Ishizaki T, Sasaki T, KOYA G, Matsuyama K, Iguchi S
Br J Clin Pharmacol. 1982; 13(3):361-74.
PMID: 7059436
PMC: 1402126.
DOI: 10.1111/j.1365-2125.1982.tb01387.x.
Acetylator phenotype and lupus erythematosus.
Uetrecht J, Woosley R
Clin Pharmacokinet. 1981; 6(2):118-34.
PMID: 7011656
DOI: 10.2165/00003088-198106020-00003.
A rapid method for determination of acetylation phenotype using dapsone.
Philip P, Roberts M, Rogers H
Br J Clin Pharmacol. 1984; 17(4):465-9.
PMID: 6721993
PMC: 1463405.
DOI: 10.1111/j.1365-2125.1984.tb02373.x.
The effect of acetylator phenotype on the disposition of aminoglutethimide.
Adam A, Rogers H, Amiel S, Rubens R
Br J Clin Pharmacol. 1984; 18(4):495-505.
PMID: 6487491
PMC: 1463619.
DOI: 10.1111/j.1365-2125.1984.tb02497.x.
Peripheral motor neuropathy caused by excessive intake of dapsone (Avlosulfon).
Rosen I, Sornas R
Arch Psychiatr Nervenkr (1970). 1982; 232(1):63-9.
PMID: 6293406
DOI: 10.1007/BF00343366.
